In MTC, the most common genetic alterations are the RET oncogene gain of function point mutations, both in sporadic MTC cases, in which a somatic RET mutation is found in about 40–70% of patients, and in familiar/hereditary MTC cases, in which a germline mutation is present in 95% of kindred [50]. This evidence concerns the gene RET and medullary thyroid gland carcinoma.